Clomipramine

證據等級: L5

預測適應症: 10 個

Clomipramine: From OCD and Depression to Anxiety Disorder

One-Sentence Summary

Clomipramine is a potent tricyclic antidepressant (TCA) with strong serotonin reuptake inhibition, historically used internationally for obsessive-compulsive disorder (OCD) and depression, though it is not currently registered in Australia. The TxGNN model predicts it may be effective for Anxiety Disorder, with 18 clinical trials identified and 20 publications currently supporting this direction. Evidence is rated at L1, underpinned by multiple completed Phase 3/4 randomised controlled trials and Cochrane-level systematic reviews.

Quick Overview

Item	Content
Original Indication	OCD and depressive disorders (international approvals; not registered in Australia)
Predicted New Indication	Anxiety Disorder
TxGNN Prediction Score	99.93%
Evidence Level	L1
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack. Based on known clinical and pharmacological information, Clomipramine is a tricyclic antidepressant (TCA) that acts as the most potent serotonin reuptake inhibitor (SRI) in its class. By increasing synaptic serotonin concentrations, it suppresses the fear circuitry — particularly the amygdala–prefrontal cortex pathway — which underpins pathological anxiety. This is the same core mechanism shared by SSRIs in their approved anxiety and OCD indications. Notably, head-to-head comparisons have demonstrated Clomipramine’s antiobsessional efficacy to be superior to some SSRIs in certain patient populations.

The predicted indication, “Anxiety Disorder,” is a broad diagnostic category encompassing OCD, panic disorder, agoraphobia, social phobia, and generalised anxiety disorder. Clomipramine has a well-documented clinical history across these subtypes: it was historically considered the gold-standard pharmacotherapy for OCD before SSRIs became widely available, and was once the reference comparator drug in European panic disorder trials. The TxGNN model’s prediction therefore aligns closely with decades of established clinical practice.

While DSM-5 and ICD-11 have reclassified OCD outside the “Anxiety Disorder” umbrella, the serotonergic pharmacological pathway remains highly relevant to both categories. The breadth of anxiety-spectrum disorders for which Clomipramine has been rigorously studied — supported by Cochrane reviews, network meta-analyses, and multiple completed Phase 3/4 RCTs — provides a compelling mechanistic and clinical rationale for this prediction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00466609	Phase 4	Completed	54	Double-blind, double-dummy RCT comparing pharmacological augmentation strategies for OCD non-responders: fluoxetine maintenance, fluoxetine + quetiapine, and fluoxetine + Clomipramine combination — directly tests Clomipramine’s clinical efficacy in anxiety-spectrum OCD
NCT00004310	Phase 2	Unknown	76	Randomised comparison of IV versus oral pulse-loading of Clomipramine in OCD patients, followed by 12-week maintenance — most directly evaluates Clomipramine pharmacotherapy for anxiety disorder subtype
NCT03299166	Phase 2/3	Completed	426	Large RCT of Troriluzole as adjunctive therapy in OCD patients with inadequate response to SSRIs, Clomipramine, or venlafaxine; Clomipramine was a key background treatment option
NCT00254735	Phase 3	Completed	44	Quetiapine augmentation of SSRI/Clomipramine baseline in severe OCD — reinforces Clomipramine’s established role as frontline pharmacotherapy for severe OCD
NCT00564564	Phase 4	Completed	21	Open RCT comparing Clomipramine augmentation vs Quetiapine augmentation of SSRIs in OCD patients who did not achieve full remission — head-to-head augmentation evidence
NCT01148316	N/A	Completed	144	Adaptive treatment strategies for children and adolescents with psychiatric disorders including OCD; Clomipramine was among pharmacotherapy options evaluated in routine clinical practice
NCT01404871	N/A	Completed	26	Biomarker prediction of medication response in OCD — participants randomly assigned to Clomipramine or escitalopram, providing comparative pharmacodynamic data
NCT00074815	Phase 3	Completed	124	RCT examining whether CBT improved outcomes in children with OCD who were partial responders to SRI treatment including Clomipramine
NCT06659094	N/A	Completed	95	Stepped-care internet-based CBT for OCD vs group CBT — reflects active research in OCD/anxiety populations, with medication (potentially including Clomipramine) as stable background treatment
NCT02431845	N/A	Recruiting	200	Pharmacoepigenetic, proteomic, and microbiomic study examining SSRI responsiveness in OCD — ongoing precision medicine research context

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38014714	2023	Cochrane Network Meta-Analysis	Cochrane Database of Systematic Reviews	Comprehensive network meta-analysis of pharmacological treatments for panic disorder in adults; provides high-level evidence positioning Clomipramine within the treatment landscape
27663940	2016	Systematic Review & Meta-Analysis	J Am Acad Child Adolesc Psychiatry	Meta-analysis of early treatment responses to SSRIs and Clomipramine in paediatric OCD; examined time course, dose-response, and comparative efficacy between agents
3887445	1985	RCT	Psychiatry Research	12-week double-blind RCT comparing Clomipramine vs Imipramine in 23 OCD outpatients; demonstrated specific antiobsessional effect of Clomipramine
9786103	1998	Double-blind RCT	J Clin Pharm Ther	Investigated whether Clomipramine + Nortriptyline combination was superior to Clomipramine alone in OCD, exploring the noradrenergic contribution to antiobsessional therapy
10665629	1999	RCT	J Clin Psychiatry	12-week placebo-controlled RCT directly comparing Paroxetine, Clomipramine, and cognitive therapy for DSM-III-R panic disorder with/without agoraphobia
2286699	1990	Double-blind RCT	J Clin Psychopharmacol	Double-blind, placebo-controlled 10-week study in 25 moderate-to-severe OCD patients; confirmed specific pharmacological effect and predominantly serotonergic mediation of Clomipramine’s antiobsessional action
1474179	1992	Clinical Trial	J Clin Psychopharmacol	Comparative study of Clomipramine, Clonazepam, and Clonidine vs Diphenhydramine (control) for OCD; Clomipramine showed superior response confirming serotonergic mechanism
8263222	1993	Meta-Analysis	J Behav Ther Exp Psychiatry	Meta-analysis of 25 treatment studies (1975–1991) comparing Clomipramine, Fluoxetine, and behaviour therapy for OCD; all three were significantly effective across multiple outcome measures
2178909	1990	Comprehensive Review	Drugs	Overview of Clomipramine’s pharmacological properties and 20-year clinical experience in OCD and panic disorder; documents superiority over older TCAs in anxiety-spectrum conditions
34582562	2021	Cochrane Systematic Review	Cochrane Database of Systematic Reviews	Updated Cochrane review on pharmacotherapy for trichotillomania (OCD-spectrum disorder); Clomipramine among systematically evaluated treatments, contributing to the broader anxiety disorder evidence base

Australia Market Information

Clomipramine is not currently registered with the TGA and has no active ARTG entries in Australia. There are no approved Australian Product Information (PI) documents available. Clinicians wishing to use Clomipramine in Australia would need to apply through the TGA Special Access Scheme (SAS) or Authorised Prescriber pathway, or consider a new ARTG registration application. For safety and dosing guidance, reference should be made to the approved PI from comparable international regulators such as the US FDA or the European Medicines Agency (EMA).

Safety Considerations

As Clomipramine is not registered in Australia, TGA-specific safety documentation is unavailable. Please refer to the approved Product Information (PI) from international regulatory authorities (US FDA or EMA) for comprehensive safety information, including warnings, contraindications, and drug interactions.

Prescribers should be aware that Clomipramine, as a TCA, carries well-recognised class-level risks relevant to routine clinical use:

Cardiac toxicity: QTc prolongation and conduction abnormalities — ECG monitoring recommended, particularly at higher doses
Seizure threshold lowering: Dose-dependent risk; caution in patients with epilepsy or predisposing conditions
Anticholinergic burden: Urinary retention, constipation, dry mouth, blurred vision, cognitive impairment — significant consideration in elderly patients
Overdose lethality: TCAs have a narrow therapeutic index; risk of fatal cardiac arrhythmia in overdose — prescribing quantity should be limited in patients at suicide risk
Drug interactions: Inhibitors of CYP2D6 and CYP1A2 may significantly elevate Clomipramine plasma levels; combination with MAOIs is contraindicated

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Clomipramine has robust, L1-level evidence across anxiety-spectrum disorders — particularly OCD, panic disorder, and agoraphobia — supported by multiple completed Phase 3/4 RCTs, Cochrane systematic reviews, and large-scale network meta-analyses. The mechanistic rationale is sound: its potent SRI action directly targets the serotonergic pathways central to anxiety disorder pathophysiology. However, the drug is not currently registered in Australia and formal safety documentation under the TGA framework is unavailable, requiring additional regulatory steps before clinical use.

To proceed, the following is needed:

Regulatory pathway: Determine whether access will be pursued via TGA Special Access Scheme (SAS Category B), Authorised Prescriber pathway, or a new ARTG registration application
Safety review: Obtain and systematically review the FDA/EMA-approved Product Information to document warnings, contraindications, and key drug–drug interactions — this is currently a blocking data gap
MOA documentation: Confirm mechanism of action via DrugBank API to strengthen the mechanistic rationale in any regulatory or clinical governance submission
Indication specificity: Clarify the precise anxiety disorder subtype being targeted (OCD, panic disorder, GAD, or agoraphobia), as evidence strength and treatment guidelines vary meaningfully by subtype
Comparative effectiveness analysis: Assess Clomipramine’s benefit–risk profile relative to currently TGA-registered first-line agents (SSRIs, SNRIs) in the Australian context, given Clomipramine’s less favourable tolerability profile
Risk management plan: Develop a structured plan addressing TCA-class cardiovascular monitoring, seizure risk stratification, anticholinergic burden assessment, and overdose risk mitigation — particularly relevant given the Australian mental health prescribing environment
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.